P. vivax morbidity after radical treatment: a 2-year cohort studies in Central Vietnam.
Background: In Vietnam, the public health importance of P. vivax has recently increased as a result of the successful malaria control program applied over the past 20 years and the recent country’s commitment to malaria elimination by 2030. We conducted a 2-year prospective cohort study to determine the risk of vivax recurrences after radical treatment and identify related risk factors. Materials & Methods:The study was conducted between April 2009 and December 2011 in 4 neighbouring villages situated in a remote forested area of Quang Nam province, Central Vietnam. P. vivax infected patients were identified through active and passive detection, and invited into a 2-year monthly follow-up after radical cure treatment (chloroquine + primaquine) following national guidelines. Monthly blood samples were systematically analysed for malaria parasites by LM and PCR. Time to first vivax recurrence was estimated by Kaplan Meir (KM) survival analysis, and significant risk factors were identified using multivariate Cox regression and the categorical and regression tree (CART) method. Results: A total of 260 P. vivax patients were enrolled between April 2009 and December 2010, ofwhom 240 completed the radical treatment, 219 completed at least 12 months of follow-up and 107 completed 24 months. In total, 179 patients (74.6%) experienced recurrent vivax infections identified by PCR which were microscopically detectable in 132 (55%) patients, and symptomatic in 85 (35.4%). The median time to first PCR detected recurrence was 120 days (IQR [60; 240]) and 210 days (IQR [103; 33]) for the first symptomatic recurrence. The KM analysis estimated an 80% (95CI [74; 86]) cumulative risk of recurrence (by PCR) by month 24, and this was only 41% for symptomatic recurrences. A space-time analysis showed significant clustering of vivax recurrences, both at household and individual level. The full analysis will be presented. Conclusions: A high number of P. vivax recurrences, mainly sub-microscopic and asymptomatic, were observed after radical cure with high dose primaquine. Malaria elimination efforts need to address this largely undetected transmission of P. vivax in order to accelerate the 2030 elimination agenda.